Immune System News and Research

RSS

Two-drug combination may alleviate radiation sickness in people

A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston.

24 Nov 2011

TLRs contribute to brain damage following hypoxia in newborns

Two out of every thousand babies are at risk of brain damage in connection with birth. Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have identified mechanisms behind these injuries, which could lead to better treatment and a richer life for the infants affected.

23 Nov 2011

University of Rochester receives U.S. patent for HPV vaccine research

The University of Rochester has been awarded a U.S. patent for research essential to both human papillomavirus vaccines on the market.

23 Nov 2011

Dendritic cells play a novel protective role in pancreas

NYU Langone Medical Center researchers have discovered the novel protective role dendritic cells play in the pancreas. The new study, published in the November issue of journal Gastroenterology, shows dendritic cells can safeguard the pancreas against acute pancreatitis, a sudden dangerous swelling and inflammation of the pancreas gland.

23 Nov 2011

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.

23 Nov 2011

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome for their uncontrolled growth. Biochemists at the Technische Universitaet Muenchen (TUM) have now identified the lead structure of a new class of drugs that attacks the proteasome in an unusual way. New medication could be developed on the basis of this previously unknown binding mechanism.

22 Nov 2011

Arginine may reactivate T-cells in patients with glioblastoma

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis.

22 Nov 2011

Researchers discover molecular sensor that detects wound-induced hydrogen peroxide

Hydrogen peroxide isn't just that bottled colorless liquid in the back of the medicine cabinet that's used occasionally for cleaning scraped knees and cut fingers. It's also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system's first responders, to rush to the wound to fight microorganisms, remove damaged tissue and then start the inflammation process.

22 Nov 2011

Study: Vaccine development efforts currently focus on incidence rather than mortality rates

Drug companies currently developing therapeutic cancer vaccines may be determining the cancers they target based on the number of annual cases, not the number of deaths they cause.

22 Nov 2011

Scientists identify new immune system defect in aged mice

As people age, their immune system becomes less robust. This makes them more susceptible to serious and frequently life-threatening infections with viruses that affect the respiratory tract such as influenza A virus.

22 Nov 2011

Titanium particles from artificial joints may play a direct role in painful inflammation

Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.

22 Nov 2011

Scientists search for main culprit behind Sj-gren's syndrome

Researchers want to find the main culprit behind the dry, irritated eyes, mouth, throat, skin, nose and more afflicting 1-3 percent of the population.

22 Nov 2011

Study identifies major risk factor for necrotizing enterocolitis

Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.

22 Nov 2011

New insights into immune-system changes that may trigger cartilage breakdown

Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.

21 Nov 2011

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

21 Nov 2011

Yeast protein in vaccines for more efficient immune response

To enhance the efficiency of vaccines, researchers at the division of chemical technology, Luleå University of Technolgy (LTU) have in co-operation with Karolinska Institute and Recopharma AB developed a strategy with the aim of directing vaccine components to critical parts of the immune system so that a more efficient immune response can be generated. The researchers have used a special type of protein produced in yeast.

21 Nov 2011

Study examines how mice with genetic bone defects respond to infusions of BMMSC

A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.

21 Nov 2011

Scientists isolate and analyze antibody that neutralizes Sudan virus

Scientists from The Scripps Research Institute and the US Army's Medical Research Institute of Infectious Diseases have isolated and analyzed an antibody that neutralizes Sudan virus, a major species of ebolavirus and one of the most dangerous human pathogens.

20 Nov 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

First study to describe transporter system that bacteria use to ensure their survival

Bacteria responsible for middle ear infections, pink eye and sinusitis protect themselves from further immune attack by transporting molecules meant to destroy them away from their inner membrane target, according to a study from Nationwide Children's Hospital.

18 Nov 2011